Tesamorelin reduced liver fat and halted fibrosis in people with HIV

A 12-month randomised trial of the GHRH analogue in HIV-associated fatty liver.

Tesamorelin is an analogue of growth-hormone-releasing hormone (GHRH). In this double-blind, multicentre trial, 61 people with HIV and fatty liver received daily tesamorelin or placebo for 12 months.

Tesamorelin reduced liver fat and prevented fibrosis progression over the year. The authors described it as the first effective strategy against fatty liver in this population, and called for longer studies to confirm the effect on histology.

In three points

Human trial in people with HIV, 12 months, double-blind
Less liver fat and no fibrosis progression
GHRH analogue of the growth-hormone axis

Compounds mentioned

Tesamorelin

Original source: Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
PubMed · The Lancet HIV

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.